Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Infectious Disease
This page provides comprehensive data and analytics for infectious disease drug approvals. Our database is updated regularly to ensure accuracy and relevance. Market conditions change rapidly, and staying informed is crucial for making sound decisions. This page aggregates the most relevant data points and presents them in an easily digestible format.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Industry experts recommend monitoring these metrics on a monthly basis to stay ahead of market shifts. Our data shows significant movement in several key indicators over the past quarter.
Updated regularly with the latest available data. Bookmark this page for easy access to current information. Sign up for our newsletter to receive updates directly.
| Drug Name | Manufacturer | Approval Date | Indication | Type |
|---|---|---|---|---|
| Infexumab | PharmaCo A | Mar 2026 | Advanced infectious disease | Biologic |
| Infetinib | PharmaCo B | Jan 2026 | Relapsed infectious disease | Small molecule |
| Infelizumab | PharmaCo C | Nov 2025 | Moderate infectious disease | Monoclonal Ab |
| Infestat | PharmaCo D | Sep 2025 | Chronic infectious disease | Oral |
| Infeparin | PharmaCo E | Jul 2025 | Acute infectious disease | Injectable |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
